Sarepta Therapeutics. Every tracked FinTwit mention of $SRPT, newest first. 99 mentions since the first on Jul 16, 2025. See the price chart.
May 2026 · 1 mention
May 14
Adam Feuerstein ✡️ — $RGNX Duchenne gene therapy study results are out: microdystrophin expression reached an average of 71% of normal across all 31 boys at 12 wks. Functional improvements in a subset…↗
April 2026 · 2 mentions
Apr 16
Adam Feuerstein ✡️ — @bradloncar Funny how you never see the videos of kids who can't walk up stairs or get up from the floor after taking a gene therapy.
Sure, videos like the one shared by $SLDB and…↗
Apr 16
Adam Feuerstein ✡️ — Roche to launch another Elevidys trial, with eyes on European approval https://t.co/eAANNiihpt via @DrewQJoseph $SRPT↗
March 2026 · 3 mentions
Mar 25
Adam Feuerstein ✡️ — Sarepta Therapeutics $SRPT shares rise on early promise for rare disease drugs. New results from small studies could support the beleaguered company’s pivot.
https://t.co/fRuvcTmt…↗
Mar 19
Adam Feuerstein ✡️ — Let's look at how the FDA is treating $SRPT and $QURE differently.
The FDA grants accelerated approval to Amondys and Vyondys to treat Duchenne muscular dystrophy. Sarepta conduc…↗
Mar 12
Adam Feuerstein ✡️ — This week's Biotech Scorecard: Catching up on non-Prasad work.
-- $ALDX is complaining about short sellers in the run-up to an FDA approval decision. Red flag!
-- The $VRTX era o…↗
February 2026 · 2 mentions
Feb 26
Adam Feuerstein ✡️ — $SRPT Sarepta Therapeutics CEO Doug Ingram will retire after a tumultuous decade https://t.co/EBnOUKSLJg via @Jasonmmast↗
Adam Feuerstein ✡️ — In this morning's press release, this is all that $SRPT discloses about Elevidys safety, one year after liver toxicity, liver-injury related hospitalizations and deaths due to acut…↗
Jan 23
Adam Feuerstein ✡️ — Thank you! I’m particularly proud of my $SRPT work last year. Accountability journalism at its best. I’m glad you recognize it.↗
Jan 23
Adam Feuerstein ✡️ — @CloisterRes I hope $SRPT tells how many Elevidys patients have been hospitalized for liver injury. That's really the only relevant data left to be told.↗
Jan 12
Adam Feuerstein ✡️ — $SRPT Elevidys Q4 sales $110M vs consensus $120M
At his #JPM26 presentation, CEO Doug Ingram notes 80% of addressable ambulatory DMD patients remain untreated. He sees this a huge…
December 2025 · 2 mentions
Dec 17
Adam Feuerstein ✡️ — The Worst Biopharma CEO of 2025 made decisions with tragic consequences
Doug Ingram, Sarepta Therapeutics. $SRPT
Is anyone surprised? Does anyone disagree?
https://t.co/1I7VrJ…↗
Dec 8
Adam Feuerstein ✡️ — $DYN Dyne Therapeutics plans to file for approval for next-generation Duchenne drug. The medicine could be a more effective version of controversial Sarepta $SRPT drug
https://t.co…↗
November 2025 · 12 mentions
Nov 20
Adam Feuerstein ✡️ — This week's Biotech Scorecard newsletter:
Richard Pazdur surely has many items on his to-do list now that he’s the top drug regulator at the Food and Drug Administration.
One o…↗
Nov 18
Adam Feuerstein ✡️ — FDA’s stronger warning on Sarepta $SRPT gene therapy raises new questions about heart risk https://t.co/xY4146JVTI via @Jasonmmast and me↗
Adam Feuerstein ✡️ — Lastly, I revisited $SRPT and the absurd claim of a "positive trend" for Amondys and Vyondys.
The treatment difference between Amondys and Vyondys, Sarepta’s exon-skipping drugs,…
October 2025 · 5 mentions
Oct 10
Adam Feuerstein ✡️ — Sarepta $SRPT to seek approval for gene therapy in rare form of muscular dystrophy
“The company has said it plans to file for approval in the disease, known as limb girdle muscula…↗
Oct 9
Adam Feuerstein ✡️ — @tmulpuri @JenniferHandt @Sarepta The NY State vote on $SRPT Elevidys was last Friday. Technically, “last week” but it took my colleague a day plus to get clarity on what the decis…↗
Adam Feuerstein ✡️ — Adam, why are you not reporting on the $SRPT Elevidys 3-yr data being presented today at WMS?
Because these very same data were already presented at conferences in May and March…
Adam Feuerstein ✡️ — @Alpha_bro1 @MattB79569101 @commonsenseplay @Sanctuary_Bio The FDA approved Elevidys despite the failure of its clinical trial. Secondary endpoints can’t “succeed” if the primary e…↗
Aug 25
Adam Feuerstein ✡️ — @MattB79569101 @commonsenseplay @Sanctuary_Bio No. The $SRPT EMBARK study failed to demonstrate Elevidys’ benefit. The negative results were reported in 2023 and published. What yo…↗
Aug 25
Adam Feuerstein ✡️ — @commonsenseplay @Sanctuary_Bio During the last reporting reporting period (June 30), Avoro, Farallon, Ecor1, Alkeon, Camber and many other funds all closed out their $SRPT long po…↗
Adam Feuerstein ✡️ — Are we sure Vinay Prasad’s ouster is positive for biotech?
Some musings in this week's newsletter.
A commonly held view of his three-month tenure running the FDA’s biologics divi…↗
Jul 30
Jacob Plieth — @JPZaragoza1 You come at the king, you best not miss $SRPT↗
Jul 28
Adam Feuerstein ✡️ — Another twist...
FDA permits use of Sarepta Therapeutics’ $SRPT Duchenne therapy in younger patients after short-lived halt https://t.co/AAZpW30smm↗
Adam Feuerstein ✡️ — Sarepta’s $SRPT dismal quarter marred by drug failures and a long list of excuses https://t.co/FZor1xE0Ap↗
Nov 3
Adam Feuerstein ✡️ — $SRPT changed the primary endpoint of the ESSENCE study bc they believed the new endpoint was more sensitive -- and it still failed.↗
Adam Feuerstein ✡️ — $SRPT Sarepta suffers a setback as N.Y. panel recommends state Medicaid pause coverage of Duchenne gene therapy Elevidys https://t.co/8f1N0ugfLf via @pharmalot↗
— @matthewherper @BiotechObserver @john_hersc79276 @Biohazard3737 More excuses and gaslighting from the $SRPT cult. 6MWT was the best endpoint, until it wasn't. NSAA was the best end…
Adam Feuerstein ✡️ — @Biohazard3737 Couple of responses:
"If Elevidys is disease modifying..." This gets to the root of all $SRPT criticism, legitimately. The company has never conducted a successful…↗
Aug 21
Adam Feuerstein ✡️ — From Jason's $SRPT story:
Even as Sarepta fought to keep its Duchenne treatment Elevidys on the market, despite the deaths of two teenagers, it pulled out of a nearly decade-long…↗
Aug 21
Adam Feuerstein ✡️ — Read the story here:
As Sarepta Therapeutics $SRPT fights for Duchenne therapy, a group of patients gets left behind
Families with limb-girdle muscular dystrophy hoped for gene t…↗
Aug 21
Adam Feuerstein ✡️ — $SRPT refinanced debt while abandoning patients with limb girdle muscular dystrophy and their families.
CEO Doug Ingram talks about "tranforming the lives of patients with rare di…↗
Aug 6
Adam Feuerstein ✡️ — Sarepta $SRPT hired a Trump-connected firm to lobby on Duchenne treatment https://t.co/mHKwoEEzAK via @john_wilkerson↗
Adam Feuerstein ✡️ — $SRPT The death referred to in the FDA statement may be the boy from Brazil who was disclosed earlier today by Brazilian authorities.
Details in that announcement were scant, but…↗
Jul 25
Adam Feuerstein ✡️ — $SRPT FDA Investigating Death of 8-Year-Old Boy Who Received Elevidys
So sad.
https://t.co/TSLPxoXv0J↗
Jul 25
Adam Feuerstein ✡️ — Amazing to watch anonymous cowardly trolls (not you, @PCM_bio ) criticize STAT for negative bias against $SRPT and then when we bring a Duchenne mother’s voice DIRECTLY to listene…↗
Jul 25
Adam Feuerstein ✡️ — $SRPT Fully updated story w/ Brazil, Japan suspensions, Elevidys patient death in Brazil said to be due to influenza
Europe moves to reject embattled Duchenne muscular dystrophy…↗
Jul 25
Adam Feuerstein ✡️ — Europe moves to reject embattled Duchenne muscular dystrophy gene therapy https://t.co/jrKJVuY9ck via @DrewQJoseph $RHHBY $SRPT↗
Jul 24
Adam Feuerstein ✡️ — For many Duchenne families, halt to Sarepta $SRPT gene therapy treatments is heartbreak upon heartbreak https://t.co/wdq8Hmd55r
My colleague @Jasonmmast with more reporting on th…↗
Jul 24
Adam Feuerstein ✡️ — The podcast interview I mentioned earlier:
A mother’s perspective on Sarepta’s $SRPT gene therapy halt https://t.co/R1QLcBCIxI via @statnews↗
Jul 24
Adam Feuerstein ✡️ — This week's Biotech Scorecard digs deeper into the Sarepta $SRPT #Duchenne gene therapy debacle.
1. Sarepta may not survive. If Elevidys cannot return to the market (and STAT's r…↗
Jul 23
Adam Feuerstein ✡️ — $SRPT Bloomberg story just published confirmed our reporting from yesterday.↗
Jul 23
Jacob Plieth — Because it's always scientifically sound to run stats on a dataset designed to show something completely different $SRPT↗
Jul 22
Adam Feuerstein ✡️ — Read more about $SRPT and the FDA officials comments here.
https://t.co/wpvzowDcdj↗
Jul 22
Adam Feuerstein ✡️ — To recap what we are reporting on $SRPT and its Duchenne gene therapy.
A senior FDA official told us that Elevidys faces an “arduous and treacherous path” to try to get it back o…↗
Jul 22
Adam Feuerstein ✡️ — Sarepta Therapeutics, $SRPT the maker of a gene therapy for Duchenne muscular dystrophy that is being temporarily shelved because of safety concerns, faces an “arduous and treacher…↗
Jul 22
Adam Feuerstein ✡️ — EXCLUSIVE: Sarepta Therapeutics’ $SRPT Duchenne therapy faces ‘arduous’ path back to market, senior FDA official says https://t.co/wpvzowDK2R via @Jasonmmast and me.↗
Jul 22
Adam Feuerstein ✡️ — $REPL rejection follows the rejection of $CAPR and $RARE drugs, and the FDA's actions against $SRPT.
CBER Director Vinay Prasad is setting a different tone than his predecessor.↗
Jul 22
Adam Feuerstein ✡️ — $SRPT With Elevidys paused, risk to balance sheet and solvency is an issue again.
Obviously, will depend on how long Elevidys remains off the market, and whether Sarepta can rest…↗
Jul 22
Adam Feuerstein ✡️ — Why did $SRPT reverse course?
Sarepta says this "proactive" step will give it time to confer with FDA and remove Elevidys from its regulatory limbo (meaning, hopefully, keeping t…↗
Jul 22
Adam Feuerstein ✡️ — BREAKING: In surprise reversal, Sarepta $SRPT says it will pause shipments of Duchenne gene therapy https://t.co/cJW1ofyOUF via @Jasonmmast and me↗
Adam Feuerstein ✡️ — $SRPT It’s always my fault. Or, the media’s fault. 🙄
Well, folks…
I didn’t cause Sarepta’s clinical trials to fail. I didn’t decide to approve Elevidys for a broad swath of DMD…↗
Jul 20
Adam Feuerstein ✡️ — @Biohazard3737 I thought we were debating $SRPT and the downstream impact on biotech?↗
Jul 19
Adam Feuerstein ✡️ — @rabmanduky I was thinking the same. And if you recall, Biogen publicly reported Tysabri PML cases every month. It was a transparent process. That's not something Sarepta $SRPT ha…↗
Jul 19
Adam Feuerstein ✡️ — I'm just seeing this now, but Joe Schwartz at Leerink is doing hero's work today on $SRPT. https://t.co/obOQCcuv6B↗
Jul 18
Adam Feuerstein ✡️ — UPDATED:.
Sarepta Therapeutics $SRPT crisis is huge blow to Duchenne families, company
Company has refused FDA request that it pull gene therapy from the market following patien…↗
Jul 18
Adam Feuerstein ✡️ — Let’s also note $SRPT CEO Doug Ingram insisted the company was the “most transparent” yet said nothing about any of this…↗
Jul 18
Adam Feuerstein ✡️ — More $SRPT news:
FDA Requests Sarepta Therapeutics Suspend Distribution of Elevidys and Places Clinical Trials on Hold for Multiple Gene Therapy Products Following 3 Deaths
Sarep…↗
Jul 18
Adam Feuerstein ✡️ — NEW: Sarepta Therapeutics $SRPT crisis is huge blow to Duchenne families, company
Our attempt to put the past 20-ish insane hours into perspective.
https://t.co/TH7rjarWHv via…↗
Jul 18
Adam Feuerstein ✡️ — Needless to say, the last 12 hours have been stunning for $SRPT. Shocking. Frustrating. Aggravating. Maddening.
The fallout will impact gene therapy and all of biotech.↗
Jul 18
Adam Feuerstein ✡️ — We have confirmed the earlier Reuters report. The FDA is requesting $SRPT halt ALL shipments of Elevidys. This includes ambulatory Duchenne patients.↗
Jul 18
Adam Feuerstein ✡️ — CONFIRMED:
FDA to request Sarepta Therapeutics $SRPT halt shipments of Duchenne gene therapy https://t.co/TH7rjarWHv↗
Jul 18
Adam Feuerstein ✡️ — $SRPT FDA will request Sarepta Therapeutics voluntarily stop all shipments of Elevidys - Reuters, citing a source familiar with the matter
Stock halted.↗
Jul 18
Adam Feuerstein ✡️ — Folks, note that the FDA said in June that it was investigating $SRPT Elevidys.
If Makary today is referring to considering a withdrawal of Elevidys for ambulatory Duchenne patie…↗
Jul 18
Adam Feuerstein ✡️ — $SRPT CEO Doug Ingram concludes today's conference call by saying, "We are a very transparent organization."↗
Jacob Plieth — @Sanctuary_Bio That's why I find the latest attempts to divert attention away from management and on to Richard Marks a bit lame. They're all culpable $SRPT↗
Jul 18
Adam Feuerstein ✡️ — This is from the Q&A portion of $SRPT investor call on Wednesday. Sarepta CEO Doug Ingram is asked if safety played any role in the decision to cut the Limb-Girdle gene therapy…↗
Jul 18
Jacob Plieth — Risk-adjusted NPV calculation didn’t justify the costs.
But remember, folks, IT'S ABOUT THE BOYS!
$SRPT↗
Jul 18
Adam Feuerstein ✡️ — Also:
Asked on a Wednesday investor call if the decision was driven by any safety concerns, CEO Doug Ingram said the company had made “a risk-adjusted net present value” calculat…↗
Jul 18
Adam Feuerstein ✡️ — Important point from our $SRPT story:
Although they deliver different genes, Elevidys and the company’s experimental limb girdle gene therapies rely on the same engineered virus t…↗
Jul 18
Adam Feuerstein ✡️ — Patient dies in Sarepta $SRPT gene therapy trial, adding to safety concerns https://t.co/cCnhL8CkGb via @Jasonmmast↗
Jul 18
Adam Feuerstein ✡️ — $SRPT More confirmation here from @Jared_Whitlock of what we heard. The patient death occurred one month ago.
Let that sink in when you think back to yesterday.↗
Jul 18
Adam Feuerstein ✡️ — This is a story my colleague @Jasonmmast was chasing as well. A third patient death from liver failure caused by $SRPT gene therapy, confirmed.
The patient had limb-girdle diseas…↗
Jul 17
Jacob Plieth — $SRPT now basically a debt vs equity story, but I guess it's always good news https://t.co/kB8tRFJ3bo↗
Jul 16
Adam Feuerstein ✡️ — $SRPT 8K is where the promotions and salary bumps were disclosed, by the way.
https://t.co/0ZCNPrKQek↗
Jul 16
Adam Feuerstein ✡️ — $SRPT After firing 500 employees, cutting programs and decimating the stock price, all after two wheelchair-bound boys died bc of Elevidys.
CEO Doug Ingram keeps his job
Ian Este…↗
Adam Feuerstein ✡️ — Now official and then some...
Sarepta Therapeutics $SRPT lays off one-third of workforce in drastic cost-cutting move https://t.co/Bv9otdq2b9 w/ @Jasonmmast↗
Jul 16
Adam Feuerstein ✡️ — Sarepta $SRPT employees are dealing with a lot today. My sympathies to you all.
If you want or need to vent, I can be reached on Signal at stataf.54
My DMs here are also open.↗
Jul 16
Adam Feuerstein ✡️ — $SRPT - As @Sanctuary_Bio mentioned last night, a significant restructuring, including employee layoffs, appears to be underway. This, of course, follows the deaths of two patient…↗